» Articles » PMID: 34791505

Epitranscriptomics of Cardiovascular Diseases (Review)

Overview
Journal Int J Mol Med
Specialty Genetics
Date 2021 Nov 18
PMID 34791505
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

RNA modifications have recently become the focus of attention due to their extensive regulatory effects in a vast array of cellular networks and signaling pathways. Just as epigenetics is responsible for the imprinting of environmental conditions on a genetic level, epitranscriptomics follows the same principle at the RNA level, but in a more dynamic and sensitive manner. Nevertheless, its impact in the field of cardiovascular disease (CVD) remains largely unexplored. CVD and its associated pathologies remain the leading cause of death in Western populations due to the limited regenerative capacity of the heart. As such, maintenance of cardiac homeostasis is paramount for its physiological function and its capacity to respond to environmental stimuli. In this context, epitranscriptomic modifications offer a novel and promising therapeutic avenue, based on the fine‑tuning of regulatory cascades, necessary for cardiac function. This review aimed to provide an overview of the most recent findings of key epitranscriptomic modifications in both coding and non‑coding RNAs. Additionally, the methods used for their detection and important associations with genetic variations in the context of CVD were summarized. Current knowledge on cardiac epitranscriptomics, albeit limited still, indicates that the impact of epitranscriptomic editing in the heart, in both physiological and pathological conditions, holds untapped potential for the development of novel targeted therapeutic approaches in a dynamic manner.

Citing Articles

Epigenetic regulation of cardiovascular diseases induced by behavioral and environmental risk factors: Mechanistic, diagnostic, and therapeutic insights.

Bi F, Gao C, Guo H FASEB Bioadv. 2024; 6(11):477-502.

PMID: 39512842 PMC: 11539034. DOI: 10.1096/fba.2024-00080.


Epitranscriptomic Regulations in the Heart.

Benak D, Kolar F, Hlavackova M Physiol Res. 2024; 73(Suppl 1):S185-S198.

PMID: 38634649 PMC: 11412340. DOI: 10.33549/physiolres.935265.


The role of RNA-modifying proteins in renal cell carcinoma.

Alhammadi M, Bajbouj K, Talaat I, Hamoudi R Cell Death Dis. 2024; 15(3):227.

PMID: 38503745 PMC: 10951318. DOI: 10.1038/s41419-024-06479-y.


Epitranscriptomics as a New Layer of Regulation of Gene Expression in Skeletal Muscle: Known Functions and Future Perspectives.

Imbriano C, Moresi V, Belluti S, Renzini A, Cavioli G, Maretti E Int J Mol Sci. 2023; 24(20).

PMID: 37894843 PMC: 10606696. DOI: 10.3390/ijms242015161.


inhibitors as a potential treatment strategy in heart failure-inferences from gene expression profiling.

Komal S, Gohar A, Althobaiti S, Khan I, Cui L, Zhang L Front Cardiovasc Med. 2023; 10:1194311.

PMID: 37583580 PMC: 10425272. DOI: 10.3389/fcvm.2023.1194311.


References
1.
Papageorgiou L, Loukatou S, Koumandou V, Makalowski W, Megalooikonomou V, Vlachakis D . Structural models for the design of novel antiviral agents against Greek Goat Encephalitis. PeerJ. 2014; 2:e664. PMC: 4226726. DOI: 10.7717/peerj.664. View

2.
Xuan J, Sun W, Lin P, Zhou K, Liu S, Zheng L . RMBase v2.0: deciphering the map of RNA modifications from epitranscriptome sequencing data. Nucleic Acids Res. 2017; 46(D1):D327-D334. PMC: 5753293. DOI: 10.1093/nar/gkx934. View

3.
Teng B, Burant C, Davidson N . Molecular cloning of an apolipoprotein B messenger RNA editing protein. Science. 1993; 260(5115):1816-9. DOI: 10.1126/science.8511591. View

4.
Blech-Hermoni Y, DasGupta T, Coram R, Ladd A . Identification of Targets of CUG-BP, Elav-Like Family Member 1 (CELF1) Regulation in Embryonic Heart Muscle. PLoS One. 2016; 11(2):e0149061. PMC: 4750973. DOI: 10.1371/journal.pone.0149061. View

5.
Blanc V, Davidson N . C-to-U RNA editing: mechanisms leading to genetic diversity. J Biol Chem. 2002; 278(3):1395-8. DOI: 10.1074/jbc.R200024200. View